Inclusion Criteria:
1. Must understand and voluntarily sign informed consent form. 2. Age ≥ 65 years at the time of signing consent. 3. Must be able to adhere to the study visit schedule and other protocol requirements.
4. Previously untreated, transplant ineligible, symptomatic multiple myeloma as defined
by the criteria below.
Both criteria a and b must be met:
1. Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary
plasmacytoma. 2. Any one or more of the following myeloma defining events (MDE):
- I. Evidence of end organ damage that can be attributed to the underlying plasma cell
proliferative disorder, specifically: i.
Hypercalcemia: serum calcium >0.25 mmol/L (>1
mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11 mg/dL) ii. Renal
insufficiency: creatinine clearance 177 μmol/L (>2 mg/dL) iii. Anemia: hemoglobin
value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10g/dL iv.
Bone lesions: one or more osteolytic lesions on skeletal radiography, computed
tomography (CT), or positron emission tomography-CT (PET-CT)
- II. Biomarker criteria or MDE:
i.
Clonal bone marrow plasma cell percentage ≥ 60% ii. Involved: uninvolved serum free
light chain (FLC) ratio ≥100 (involved FLC level must be ≥100 mg/L) iii. > 1 focal
lesions on magnetic resonance imaging (MRI) studies (at least 5 mm in size)
5. Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1,
or 2.
6. Females of child-bearing potential (FCBP) must have a negative serum test and follow
the guidelines in the pregnancy prevention program. FCBP and males must either commit
to continued abstinence from heterosexual intercourse or must abide by birth control
requirements as described in Appendix 9 for the pregnancy prevention program.
7. Men must practice complete abstinence or agree to use a condom during sexual contact
with a pregnant female or a female of childbearing potential while participating in
the study, during dose interruptions and for at least 28 days following study drug
discontinuation, even if he has undergone a successful vasectomy as described in
Appendix 9 of the pregnancy prevention program.
8. Life expectancy of ≥ 3 months.
9. Able to take oral medications.
10. The following laboratory results must be met within 10 days prior to first study drug
administration:
1. Absolute neutrophil count (ANC) ≥ 1.0 x 109/L. Growth factors cannot be given
within 10 days of study drug administration.
2. Serum AST and ALT ≤ 1.5 x upper limit of normal (ULN).
3. Creatinine clearance ≥ 30 mL/min either directly measured via 24-hour urine
collection or calculated using MDRD (Appendix 1).
4. Platelet count ≥ 50 x 109/L. Platelet transfusions to help subjects meet
eligibility criteria are not allowed within 10 days before study enrollment.
5. Hemoglobin ≥ 80 g/L.
Exclusion Criteria:
1. Previous treatment with anti-myeloma therapy (does not include radiotherapy,
bisphosphonates, or a single short course of steroid [i.e. less than or equal to the
equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid
treatment must not have been given within 14 days of treatment start]).
2. Any serious medical condition that places the patient at an unacceptable risk if he or
she participates in this study. Examples of such a medical condition are, but are not
limited to, patient with unstable cardiac disease as defined by: Cardiac events such
as MI within the past 6 months, NYHA heart failure class III-IV, uncontrolled atrial
fibrillation or hypertension; patients with conditions requiring chronic steroid or
immunosuppressive treatment, such as rheumatoid arthritis, multiple sclerosis and
lupus, that likely need additional steroid or immunosuppressive treatments in addition
to the study treatment.
3. Pregnant or lactating females.
4. Renal failure requiring hemodialysis or peritoneal dialysis.
5. Prior history of malignancies, other than multiple myeloma, unless the patient has
been free of the disease for ≥ 3 years. Exceptions include the following:
1. Basal cell carcinoma of the skin. 2. Squamous cell carcinoma of the skin. 3. Carcinoma in situ of the cervix. 4. Carcinoma in situ of the breast. 5. Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
6. Patients who are unable or unwilling to undergo antithrombotic therapy.
7. Peripheral neuropathy of ≥ grade 2 severity.
8. Known HIV positivity or active infectious hepatitis, type A, B, or C.
9. Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by
amyloidosis.
10. Plasma Cell Leukemia. 11. Evidence of cardiovascular risk including any of the following:
1. QTc interval ≥ 470 msecs. Note that the QT interval should be corrected for heart
rate by Fridericia's formula (QTcF)
2. Evidence of current clinically significant uncontrolled arrhythmias; including
clinically significant ECG abnormalities; including 2nd degree (Type II) or 3rd
degree atrioventricular (AV) block.
3. History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, or stenting or bypass grafting within six months
of screening.
4. Class III or IV heart failure as defined by the New York Heart Association
functional classification system (Appendix 2)
5. Uncontrolled hypertension. 12. Patients with hypersensitivity to boron or any of its excipients or to the active
substance of Iberdomide or its excipients. 13. Patients requiring strong inhibitors or inducers of CYP3A4/5. See Appendix 10 for a
list of these drugs. 14. Any concurrent severe and/or uncontrolled medical condition or psychiatric disease
that is likely to interfere with study procedures or results, or that in the opinion
of the investigator would constitute a hazard for participating in this study or that
confounds the ability to interpret data from the study.
15. Patients that have had severe acute respiratory syndrome coronavirus 2 infection
within 14 days for mild or asymptomatic infections or 28 days for severe/critical
illness prior to initiating study treatment.
16. Patients that have undergone major surgery (as defined by the investigator) within 28
days of initiating study treatment.
17. Active systemic infection that is likely to interfere with the study procedures or
results or that, in the opinion of the investigator, would constitute a hazard for
participating in this study.
18. Patients with a gastrointestinal disease that may significantly alter the absorption
of iberdomide. 19. Patients that have received a live vaccine within 3 months of initiating study
treatment.
